As previously shown, mesothelioma exhibits strong upregulation of the target receptor uPARAP across all primary subtypes, independent of asbestos exposure, neoadjuvant chemotherapy, tumor–node–metastasis staging, or nuclear grade (8). This evidence concerns the gene MRC2 and mesothelioma.